| | | 上海荣泰健康科技股份有限公司 第四届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海荣泰健康科技股份有限公司（以下简称"公司"）第四届监事会第十七 次会议于 2025 年 8 月 27 日上午 11 时在上海市青浦区徐泾镇高光路 169 弄虹桥 时代广场荣泰大厦公司会议室召开。会议通知及会议资料已于 2025 年 8 月 15 日以现场送达、电话或电子邮件等方式发出。本次会议由监事会主席曹韬先生主 持，会议应到监事 3 人，实到监事 3 人。本次会议的召集、召开程序符合《中华 人民共和国公司法》等有关法律、法规、《上海荣泰健康科技股份有限公司章程》 的规定，会议决议合法有效。 二、监事会会议审议情况 表决结果：3 名赞成，占全体非关联监事人数的 100%；0 名弃权；0 名反对。 2、审议《关于公司 2025 年半年度募集资金存放与实际使用情况的专项报告 的议案》 具体内容详见公司同日披露的《上海荣泰健康科技股份有限公司关于 2025 年半年度募集资金存放与实 ...

| | | 上海荣泰健康科技股份有限公司 关于实施"荣泰转债"赎回暨摘牌的第二次提示性 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2025年8月27日收市后，距离9月8日（"荣泰转债"最后交易日）仅剩 8个交易日，9月8日为"荣泰转债"最后一个交易日。 最后转股日：2025 年 9 月 11 日 截至2025年8月27日收市后，距离9月11日（"荣泰转债"最后转股日）仅 剩11个交易日，9月11日为"荣泰转债"最后一个转股日。 本次提前赎回完成后，"荣泰转债"将自 2025 年 9 月 12 日起在上海证 券交易所摘牌。 投资者所持"荣泰转债"除在规定时限内通过二级市场继续交易或按照 23.07 元/股的转股价格进行转股外，仅能选择以 100 元/张的票面价格加当期 应计利息 2.1713 元/张（即合计 102.1713 元/张）被强制赎回。若被强制赎回， 可能面临较大投资损失。 公司提醒"荣泰转债"持有人注意在限期内转股或卖出。 上海荣泰健康科技股份有限公司（以下简称"公司"）股票自 202 ...

上海荣泰健康科技股份有限公司2025 年半年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2025 年半年度报告 1 / 224 上海荣泰健康科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投资风 险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 十、 重大风险提示 公司已在本报告中详细描述可能存在的相关风险,敬请投资者关注本半年度报告"第三节 管 理层讨论与分析 ...

Group 1 - The core viewpoint of the announcement indicates that Rongtai Health's operating revenue for the first half of 2025 is 810 million yuan, representing a year-on-year decrease of 1.78% [1] - The net profit for the same period is 85.3369 million yuan, showing a year-on-year decline of 23.35% [1]

Core Insights - Shanghai Rongtai Health Technology Co., Ltd. announced a strategic cooperation with Shanghai Aoshah Intelligent Technology Co., Ltd. to explore the integration of health technology and exoskeleton technology, marking a significant step in their collaboration [1][2] - Aoshah Intelligent, a leader in the consumer-grade exoskeleton field in China, aims to accelerate the penetration of exoskeleton technology into the consumer health market through this partnership [2] Company Overview - Rongtai Health has been deeply involved in the health industry for 28 years, with products sold in over 80 countries and regions, and has sold more than 3 million massage chairs [2] - Aoshah Intelligent offers a diverse product line that includes upper limb, waist, lower limb, and full-body exoskeletons, indicating a strong position in the consumer-grade market [2] Strategic Collaboration - The partnership will leverage Rongtai Health's manufacturing and market channel advantages alongside Aoshah Intelligent's technological expertise, focusing on after-sales service, production, and other collaborative dimensions [1] - Future plans include establishing deep cooperation in three core areas: technological health, industry applications, and technology research and development, aiming for complementary advantages and collaborative growth [1]

Group 1 - Rongtai Health (603579) and Aoshark Intelligence signed a strategic cooperation agreement on August 26 [1] - The collaboration aims to integrate health technology with exoskeleton technology, exploring "human-machine symbiosis" [1] - Future plans include deep cooperation in three core areas: technological health, industry applications, and technology research and development [1] Group 2 - Aoshark Intelligence is a high-tech robotics company based on an exoskeleton technology platform [1]

Core Insights - Rongtai Health has entered a strategic partnership with Shanghai Aoshark Intelligent Technology, marking a significant step in integrating health technology with exoskeleton technology [1][2] - The collaboration aims to explore the potential of "human-machine symbiosis" and promote the popularization of exoskeleton technology in public health scenarios [1] - Rongtai Health has invested 20.6 million yuan in Aoshark Intelligent, indicating a commitment to deepening their partnership [1] Company Overview - Rongtai Health has been in the health industry for 28 years and has sold over 3 million massage chairs globally, reaching more than 80 countries and regions [1] - The company is focused on building a "big health ecosystem" through strategic collaborations [1] Aoshark Intelligent Overview - Aoshark Intelligent is a leading company in the consumer-grade exoskeleton field in China, known for its advanced technology and performance in major events like the Hangzhou Asian Games [1] - The company offers a diverse product line that includes upper limb, waist, lower limb, and full-body exoskeletons [1] Future Collaboration Plans - Rongtai Health plans to leverage its manufacturing and market channel advantages to collaborate with Aoshark Intelligent in after-sales service, production, and other areas [2] - The partnership will focus on three core areas: technological health, industry applications, and technological research and development [2]

Key Points - The company Shanghai Rongtai Health Technology Co., Ltd. has announced the early redemption of its convertible bonds "Rongtai Convertible Bonds" [1][2] - The redemption registration date is set for September 11, 2025, with a redemption price of 102.1713 CNY per bond [1][4] - The last trading day for the bonds is September 8, 2025, and the last conversion day is also September 11, 2025 [1][6] - The company has triggered the conditional redemption clause due to its stock price exceeding 130% of the conversion price for a specified period [2][3] - The accrued interest for the bonds is calculated based on a formula that includes the principal amount, interest rate, and the number of days until redemption [3][4] - The company will withhold personal income tax on the interest income for individual investors, resulting in a net redemption amount of 101.7370 CNY per bond after tax [4][5] - The bonds will be delisted from the Shanghai Stock Exchange starting September 12, 2025, following the completion of the redemption [1][7]

证券代码：603579 证券简称：荣泰健康 公告编号：2025-053 债券代码：113606 债券简称：荣泰转债 上海荣泰健康科技股份有限公司 关于实施"荣泰转债"赎回暨摘牌的第一次提示性 公告 截至2025年8月26日收市后，距离9月11日（"荣泰转债"最后转股日）仅 剩12个交易日，9月11日为"荣泰转债"最后一个转股日。 本次提前赎回完成后，"荣泰转债"将自 2025 年 9 月 12 日起在上海证 券交易所摘牌。 投资者所持"荣泰转债"除在规定时限内通过二级市场继续交易或按照 23.07 元/股的转股价格进行转股外，仅能选择以 100 元/张的票面价格加当期 应计利息 2.1713 元/张（即合计 102.1713 元/张）被强制赎回。若被强制赎回， 可能面临较大投资损失。 公司提醒"荣泰转债"持有人注意在限期内转股或卖出。 上海荣泰健康科技股份有限公司（以下简称"公司"）股票自 2025 年 7 月 29 日至 2025 年 8 月 18 日，已在连续三十个交易日内有十五个交易日的收盘价 赎回登记日：2025 年 9 月 11 日 赎回价格：102.1713 元/张 赎回款发放日：2025 年 9 ...

从资金流向上来看，当日其他家电板块主力资金净流入6309.37万元，游资资金净流出5230.25万元，散户 资金净流出1079.12万元。其他家电板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603579 | 荣泰健康 | 6188 | 1.89% | 12.93万 | 4.871Z | | 002614 | 喫佳华 | 7.11 | 1.14% | 11.87万 | 8403.79万 | | 300247 | 融捷健康 | 4.77 | 1.06% | 24.33万 | 1.15亿 | | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 603579 荣泰健康 | 5875.19万 | 12.07% | -3579.60万 | -7.35% | -2295.59万 | -4.72% | | 300247 融捷健康 | 267.51万 | 2.32% | -1036.42万 | -8. ...